10.2 Non-Sterile and Sterile Compounding Standards (USP <795>, <797>)

10.2 Non-Sterile and Sterile Compounding Standards (USP <795>, <797>)

Pharmaceutical compounding occupies a specialized regulatory intersection between traditional state-level pharmacy practice and federal food and drug legislation. In the Commonwealth of Virginia, the statutory foundation for compounding is codified in the Virginia Drug Control Act (Va. Code § 54.1-3410.2) and governed by the United States Pharmacopeia (USP) general chapters—specifically USP Chapter <795> for non-sterile preparations and USP Chapter <797> for sterile preparations.

Following the 2012 New England Compounding Center (NECC) fungal meningitis tragedy, the United States Congress enacted the Drug Quality and Security Act of 2013 (DQSA, Pub. L. 113-54), amending the Federal Food, Drug, and Cosmetic Act (FD&C Act) to establish a permanent statutory bifurcation between traditional state-regulated compounding pharmacies (Section 503A, 21 U.S.C. § 353a) and federally registered outsourcing facilities (Section 503B, 21 U.S.C. § 353b). Understanding this statutory boundary, alongside the technical engineering and Beyond-Use Dating (BUD) mandates of USP <795> and <797>, is crucial for Virginia pharmacy practice and the MPJE.

---

Statutory Framework: Section 503A Traditional Pharmacy Compounding

Under Virginia Code § 54.1-3410.2 and federal Section 503A, traditional compounding is defined as the preparation, mixing, assembling, packaging, or labeling of a drug by a licensed pharmacist pursuant to a valid, patient-specific prescription order from a licensed practitioner.

The Tripartite Relationship and Anticipatory Compounding

• Patient-Specific Mandate: A Section 503A compounding pharmacy cannot compound medications in bulk for indiscriminate wholesale distribution or general office stocking. Every compounded formulation must be linked to an identified individual patient holding a valid prescription.
• Limited Anticipatory Compounding: Pharmacists are permitted to prepare limited quantities of compounded formulations in advance of receiving individual prescriptions, provided that the anticipatory compounding is based strictly on an established historical pattern of receiving valid prescriptions from specific prescribers for specific patients within an established relationship.

Prohibited Compounding Practices

Both federal law and Virginia Code § 54.1-3410.2 strictly prohibit pharmacies from engaging in improper manufacturing under the guise of compounding:

1. Compounding Regular Copies of Commercially Available Drugs: A pharmacy cannot compound a drug product that is essentially a copy of a commercially available, FDA-approved product on a regular or inordinate basis.
   • Permissible Clinical Exception: Compounding a product that mirrors a commercial drug is only legal if there is a documented clinically significant difference for an individual patient, as determined and requested by the prescribing practitioner (e.g., compounding a dye-free or preservative-free liquid for an allergic patient, or preparing an oral liquid suspension for a pediatric patient with dysphagia when the commercial drug is only manufactured as a solid oral tablet).
   • Drug Shortage Exception: If an FDA-approved drug appears on the official FDA Drug Shortage list, compounding that formulation during the declared shortage is generally not treated as compounding an available commercial copy.
2. Compounding Withdrawn or Unsafe Drugs: Pharmacies are strictly prohibited from compounding any drug product containing active chemical ingredients that have been withdrawn, revoked, or removed from the commercial market by the FDA due to safety or efficacy concerns.
3. Compounding Demonstrably Difficult Products: Under Section 503A(b)(1)(C), drugs identified by the FDA as demonstrably difficult to compound (such as metered-dose inhalers or complex liposomal injectables) are prohibited from compounding.

---

USP <795> Non-Sterile Compounding Standards

USP Chapter <795> establishes practice standards for compounding non-sterile preparations (e.g., oral solutions, suspensions, capsules, powders, suppositories, topical creams, and ointments). Compounding personnel must follow standard operating procedures (SOPs), maintain dedicated equipment, and create two essential records for every preparation:

• Master Formulation Record (MFR): The detailed "recipe" that describes how the preparation is compounded. An MFR is created once for each unique formulation and must include: chemical names and grades of ingredients, exact quantities, equipment needed, step-by-step compounding procedure, quality control checkpoints, container-closure type, storage requirements, and reference source for the assigned Beyond-Use Date (BUD).
• Compounding Record (CR): The batch-specific log generated each time a compound is prepared. It documents: MFR name and reference ID, specific lot numbers and expiration dates of all raw components, actual quantities weighed/measured, initials of the compounder and verifying pharmacist, unique internal prescription/control number, date prepared, calculated BUD, and physical inspection results.

USP <795> Beyond-Use Date (BUD) Ceilings

In the absence of established, stability-indicating chemical analytical assay data or specific USP-NF monographs, compounders must assign conservative Beyond-Use Dates based strictly on the formulation's physical properties, presence of water, and storage temperature:

Critical Analytical Distinction: An assigned BUD cannot exceed the shortest expiration date of any individual active pharmaceutical ingredient (API) or raw component used in the compound. Water is the primary driver of chemical degradation and microbial proliferation; hence, non-preserved aqueous liquids carry the most restrictive ceiling (14 days refrigerated).

---

USP <797> Sterile Compounding Standards

USP Chapter <797> governs the compounding of sterile preparations (CSPs), including intravenous infusions, ophthalmic drops, total parenteral nutrition (TPN), intramuscular injections, and intrathecal solutions. Because introducing microbial, particulate, or pyrogenic contamination into sterile tissue carries catastrophic clinical risks, USP <797> mandates cleanroom engineering controls, strict garbing sequences, and ongoing quality assurance.

Cleanroom Engineering Architecture and Air Quality

Sterile compounding cleanroom suites rely on cascading air cleanliness levels classified by the International Organization for Standardization (ISO):

Sterile Cleanroom Differential Air Pressure and Cascading Cleanliness:
┌────────────────────────────┐     ┌────────────────────────────┐     ┌────────────────────────────┐
│         Ante-Room          │     │        Buffer Room         │     │ Primary Engineering Control│
│        ISO Class 8         │────►│        ISO Class 7         │────►│       (PEC / Hood)         │
│ (Garbing, Hand Hygiene,    │     │  (Staging, Sterile Prep)   │     │        ISO Class 5         │
│  Order Entry, Staging)     │     │   Positive Pressure:       │     │ (LAFW or CAI Workspace)    │
│   Pressure: ≥ 0.02" w.c.   │     │   ≥ 0.02" w.c. rel to Ante │     │ High-efficiency HEPA flow  │
│   ACPH: ≥ 20 ACPH          │     │   ACPH: ≥ 30 ACPH          │     │ Air: ≤ 3,520 particles/m³  │
└────────────────────────────┘     └────────────────────────────┘     └────────────────────────────┘

• Primary Engineering Control (PEC): The unidirectional airflow device where compounding occurs (e.g., Laminar Airflow Workbench [LAFW] or Compounding Aseptic Isolator [CAI]). Must provide ISO Class 5 air quality (maximum 3,520 particles of size 0.5 µm or larger per cubic meter of air).
• Secondary Engineering Control (SEC) - Buffer Room: The cleanroom suite housing the PEC. Must maintain ISO Class 7 air quality (maximum 352,000 particles/m³).
• Secondary Engineering Control (SEC) - Ante-Room: The transitional area between unclassified pharmacy space and the buffer room, used for garbing, hand hygiene, and unpacking. Must maintain at least ISO Class 8 air quality (maximum 3,520,000 particles/m³). Note: If the ante-room opens into a negative-pressure hazardous drug buffer room, the ante-room must meet ISO Class 7 standards.
• Positive Pressure Differential: To prevent dirty air from infiltrating clean areas, non-hazardous sterile suites require positive pressure: the buffer room must maintain a continuous minimum positive pressure of 0.02 inches water column (w.c.) relative to the ante-room, and the ante-room must maintain ≥ 0.02" w.c. relative to adjacent unclassified spaces.
• Air Changes Per Hour (ACPH): The buffer room must achieve a minimum of 30 ACPH, with at least 15 ACPH supplied via HEPA-filtered fresh/outdoor air. An ISO Class 8 ante-room requires at least 20 ACPH.

Garbing and Aseptic Hand Hygiene Sequence

Contamination control begins with personnel. USP <797> dictates a strict garbing order moving from the dirtiest to the cleanest area across the "line of demarcation" in the ante-room:

1. Remove outer garments, personal jewelry, cosmetics, and artificial nails;
2. Don dedicated cleanroom shoe covers (or wipe dedicated footwear);
3. Don head and facial hair covers, ensuring all hair is contained;
4. Don a surgical face mask (and eye shield/goggles if splashing risk);
5. Perform aseptic hand and forearm washing: Wash hands and forearms up to the elbows with warm water and soap for at least thirty (30) seconds, clean under fingernails with a nail pick, and dry thoroughly with non-shedding, lint-free disposable towels;
6. Don a non-shedding, cleanroom-certified gown with snug cuffs and closure at the neck;
7. Enter the ISO Class 7 buffer room;
8. Sanitize hands with sterile 70% Isopropyl Alcohol (IPA);
9. Don sterile, powder-free gloves; ensure glove cuffs cover the gown sleeves;
10. Routinely disinfect gloved hands with sterile 70% IPA throughout compounding and allow to air dry.

Quality Assurance and Testing Frequencies

---

CSP Categories and Beyond-Use Dating (BUD) Architecture

Under updated USP <797>, Compounded Sterile Preparations are categorized into three operational risk tiers based on compounding environment, starting components, and sterility assurance:

1. Category 1 CSPs

• Compounded in a Segregated Compounding Area (SCA) or in a PEC that is not located within a certified cleanroom suite (e.g., a standalone laminar flow hood in an unclassified hospital satellite pharmacy).
• Maximum BUD: 12 hours or less at controlled room temperature, or 24 hours or less refrigerated (2°C to 8°C).

2. Category 2 CSPs

• Compounded in a certified cleanroom suite (ISO Class 5 PEC within an ISO Class 7 Buffer Room and ISO Class 8 Ante-Room).
• Beyond-Use Dates are determined by: (1) whether components are all sterile or include non-sterile starting APIs, (2) whether terminal sterilization (autoclave/filtration) was performed, (3) whether sterility testing was executed, and (4) storage temperature:
  • Aseptically prepared, sterile components only, no sterility testing: Typically 4 days at room temp, 10 days refrigerated, or 45 days frozen (-25°C to -10°C).
  • Aseptically prepared, one or more non-sterile components, no sterility testing: Typically 1 day at room temp, 4 days refrigerated, or 45 days frozen.
  • Sterility tested and passed: BUDs extend up to 30 to 45 days at room temp or 60 days refrigerated, depending on sterilization method.

3. Category 3 CSPs

• Preparations requiring extended BUDs beyond Category 2 limits (up to 180 days).
• Strictly requires: stability-indicating assay data, passing sterility testing (USP <71>), passing bacterial endotoxin testing (USP <85>), continuous environmental monitoring, personnel semi-annual competency testing, and dedicated cleanroom facilities.

---

Section 503A Traditional Pharmacies vs. Section 503B Outsourcing Facilities

The table below outlines the core differences between traditional state-regulated compounding and federally registered outsourcing facilities: